Hitting a Moving Target: Inhibition of the Nuclear Export Receptor XPO1/CRM1 as a Therapeutic Approach in Cancer

doi 10.20517/cdr.2018.09
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OAE Publishing Inc.

Related search

Nuclear Export of the Yeast Hexokinase 2 Protein Requires the Xpo1 (Crm1)-Dependent Pathway

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

Leptomycin B, an Inhibitor of the Nuclear Export Receptor CRM1, Inhibits COX-2 Expression

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2002English

Prostanoid Receptor EP2 as a Therapeutic Target

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2013English

XPO1 (Exportin 1 (CRM1 Homolog, Yeast))

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2012English

A Global Survey of CRM1-dependent Nuclear Export Sequences in the Human Deubiquitinase Family

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2011English

EGFR Family Inhibition Identifies P38 MAPK as a Potential Therapeutic Target in Bladder Cancer

Urology
Urology
2018English

Clinical Implications of Targeting XPO1-Mediated Nuclear Export in Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

A Role for RanBP1 in the Release of CRM1 From the Nuclear Pore Complex in a Terminal Step of Nuclear Export

Journal of Cell Biology
MedicineCell Biology
1999English

DNA Methylation as a Therapeutic Target in Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy